Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
Thermo Fisher Scientific (TMO) reported third-quarter 2026 revenue of $12.14 billion, up 9% from $11.12 billion a year earlier; organic revenue growth was 6%. GAAP diluted EPS was $4.64, up 9%, and adjusted EPS was $6.68, up 15%. GAAP operating income rose 17% to $2.26 billion, with an 18.6% operating margin versus 17.4%; adjusted operating income rose 15% to $2.97 billion, and adjusted operating margin was 24.5% versus 23.3%. Adjusted measures are non-GAAP.
For the first nine months of 2026, net cash provided by operating activities was $5.867 billion versus $4.361 billion; free cash flow was $4.618 billion versus $3.319 billion. Specialty Diagnostics revenue was $1.098 billion, compared with $1.174 billion a year earlier. Thermo Fisher completed its previously announced microbiology business divestiture during the quarter and launched new products, including a U.S. FDA-cleared autoimmune test. Its Mayo Clinic initiative will combine data from more than one million patient samples with its proteomics ecosystem. The company said updated 2026 guidance would be provided on its earnings call that morning.
Thermo Fisher Scientific Inc. director Dion J. Weisler acquired 55.56 Phantom Stock Units on September 26, 2026, credited under the Deferred Compensation Plan for Directors at $675.00 per unit. His direct position following the transaction was 2,846.55 Phantom Stock Units.
Scott M. Sperling reported acquisition or exercise transactions in this Form 4 filing. Thermo Fisher Scientific Inc. director Scott M. Sperling was credited with 62.9600 Phantom Stock Units on September 26, 2026. The units were credited at a stock price of $675.00 per unit under the Deferred Compensation Plan; his reported balance afterward was 17,737.6000 units. The units are convertible into Common Stock on a 1-for-1 basis and are distributable as stock upon cessation of director service for any reason or a change of control.
Thermo Fisher Scientific Inc. director Karen S. Lynch acquired 46.3 Phantom Stock Units credited to her account on September 26, 2026, under the Deferred Compensation Plan for Directors. The units were priced at $675.00 per unit, based on the stock’s closing price as of quarter-end, and her reported balance after the credit was 398.7 Phantom Stock Units.
R. Alexandra Keith reported acquisition or exercise transactions in this Form 4 filing. Thermo Fisher Scientific Inc. director R. Alexandra Keith was credited with 46.3 Phantom Stock Units on September 26, 2026, under the Deferred Compensation Plan for Directors, at a price of $675.00 per unit. The units are convertible into common stock on a 1-for-1 basis; the reported resulting balance was 1,377.65 units. They are distributable as stock upon cessation of director service for any reason or a change of control.
Thermo Fisher Scientific Inc. director Jennifer M. Johnson acquired 46.3 Phantom Stock Units, credited to her account on September 26, 2026, at $675.00 per unit under the company’s Deferred Compensation Plan for Directors. Her reported balance following the credit was 768.52 units.
The units are convertible into Common Stock on a 1-for-1 basis and are distributable as stock when director service ends or upon a change of control.
THERMO FISHER SCIENTIFIC INC. (TMO) reported that Chairman & CEO Marc N. Casper had 1,256.617 shares of common stock withheld or delivered on 2026-08-28 to satisfy exercise price or tax liability, in two code F transactions at $622.18 per share. The filing also lists indirect holdings of 11,300 shares by the Alison Casper 2020 Irrevocable Trust and 5,000 shares by the MNC 2020 Irrevocable Trust, for which Casper disclaims beneficial ownership except for any pecuniary interest. The Rule 10b5-1 trading-plan checkbox was not selected.
THERMO FISHER SCIENTIFIC INC. (TMO) reported insider activity by Sr. Vice President & CFO James Meyer on August 28, 2026. He had five code F transactions in common stock, delivering or withholding a total of 270.28 shares at $622.18 per share for payment of exercise price or tax liability. A separate entry reports indirect ownership of 58.47 shares held through the TMO 401(k) plan, including 0.10 shares acquired between August 21 and August 28, 2026.
THERMO FISHER SCIENTIFIC INC. (TMO) reported an insider transaction by Thomas B. Shropshire Jr., SVP and General Counsel. On 2026-08-28, 49.024 shares of common stock were disposed of at $622.18 per share to satisfy exercise price or tax liability by delivering or withholding shares, rather than through an open-market sale. After this transaction, Shropshire directly owned 6,008.5 shares of Thermo Fisher common stock.
THERMO FISHER SCIENTIFIC INC. (TMO) reported that Executive Vice President Michael D. Shafer had four Form 4 transactions on 2026-08-28. In total, 790.041 shares of common stock were disposed of at $622.18 per share through code F transactions, representing shares delivered or withheld to pay the exercise price or tax liability in connection with equity awards.